All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

cholestyramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	727	11041-12-6

Description:

Molecule	Description
Synonyms: colestyramine cholestyramine cholestyramine chloride colestyramin	Molecular weight: 1162 Formula: C68H97Cl5N5 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
14	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Aug. 3, 1973	FDA	BRISTOL MYERS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	214.91	13.22	506	16116	938684	89673141
Product taste abnormal	104.85	13.22	32	16590	2428	90609397
Product physical consistency issue	94.30	13.22	24	16598	930	90610895
Product solubility abnormal	78.98	13.22	21	16601	968	90610857
Frequent bowel movements	60.75	13.22	63	16559	56872	90554953
Colitis	60.01	13.22	69	16553	69873	90541952
Product residue present	58.83	13.22	24	16598	4267	90607558
Abdominal pain	51.03	13.22	174	16448	395547	90216278
Glossodynia	47.17	13.22	3	16619	321776	90290049
Bowel movement irregularity	46.23	13.22	23	16599	6491	90605334
Abdominal distension	45.46	13.22	84	16538	130517	90481308
Drug ineffective for unapproved indication	44.60	13.22	58	16564	66586	90545239
Systemic lupus erythematosus	43.74	13.22	7	16615	361889	90249936
Laparotomy	43.22	13.22	11	16611	426	90611399
Bulimia nervosa	41.45	13.22	11	16611	503	90611322
Intestinal obstruction	41.26	13.22	42	16580	37089	90574736
Contraindicated product administered	39.11	13.22	6	16616	320133	90291692
Wound	38.61	13.22	5	16617	302975	90308850
Faecal calprotectin increased	37.23	13.22	17	16605	3970	90607855
Clostridium difficile infection	36.68	13.22	39	16583	36206	90575619
Gastrointestinal wall thickening	36.46	13.22	14	16608	2123	90609702
Product use complaint	35.96	13.22	16	16606	3517	90608308
Rheumatoid arthritis	34.05	13.22	12	16610	362602	90249223
Intestinal stenosis	33.88	13.22	15	16607	3259	90608566
Intestinal anastomosis	30.97	13.22	10	16612	912	90610913
Flatulence	30.84	13.22	38	16584	41329	90570496
Helicobacter infection	30.76	13.22	3	16619	226847	90384978
Sacroiliitis	30.25	13.22	15	16607	4204	90607621
Constipation	29.91	13.22	116	16506	280279	90331546
Toxicity to various agents	29.76	13.22	8	16614	287838	90323987
Cholangitis sclerosing	29.01	13.22	12	16610	2209	90609616
Intestinal resection	28.97	13.22	13	16609	2914	90608911
Intestinal fibrosis	28.71	13.22	7	16615	227	90611598
Mesenteric vein thrombosis	28.38	13.22	10	16612	1191	90610634
Rash macular	27.88	13.22	31	16591	30249	90581576
Ileal stenosis	27.74	13.22	12	16610	2466	90609359
Bile acid malabsorption	27.10	13.22	7	16615	288	90611537
Anal incontinence	27.02	13.22	23	16599	16207	90595618
Folliculitis	26.94	13.22	3	16619	204350	90407475
Therapeutic product effect decreased	26.37	13.22	9	16613	277562	90334263
Proctalgia	25.74	13.22	17	16605	8181	90603644
Post procedural diarrhoea	25.39	13.22	7	16615	370	90611455
Small intestinal obstruction	25.39	13.22	25	16597	21209	90590616
Cerebral venous sinus thrombosis	24.95	13.22	11	16611	2365	90609460
Functional gastrointestinal disorder	24.92	13.22	14	16608	5048	90606777
Blood alkaline phosphatase increased	24.90	13.22	37	16585	48042	90563783
Ophthalmoplegia	24.72	13.22	10	16612	1739	90610086
Type 2 diabetes mellitus	24.38	13.22	4	16618	203240	90408585
Terminal ileitis	24.26	13.22	9	16613	1241	90610584
Foreign body in throat	23.75	13.22	7	16615	471	90611354
Off label use	23.33	13.22	306	16316	1101946	89509879
Impaired healing	23.29	13.22	7	16615	234192	90377633
Nephrolithiasis	22.92	13.22	36	16586	49049	90562776
Product odour abnormal	22.26	13.22	9	16613	1562	90610263
Gastroenteritis	22.03	13.22	27	16595	29202	90582623
Ill-defined disorder	21.39	13.22	4	16618	184887	90426938
Jaundice	21.28	13.22	28	16594	32489	90579336
Stomatitis	21.21	13.22	12	16610	274686	90337139
Suprapubic pain	20.93	13.22	7	16615	713	90611112
Drug level decreased	20.89	13.22	16	16606	9714	90602111
Arthropathy	20.68	13.22	22	16600	366220	90245605
Serum ferritin increased	20.07	13.22	14	16608	7367	90604458
Pleural rub	19.10	13.22	4	16618	64	90611761
Anal fissure	18.96	13.22	12	16610	5373	90606452
Enterocutaneous fistula	18.87	13.22	8	16614	1566	90610259
Colectomy	18.47	13.22	10	16612	3357	90608468
Cystitis	18.46	13.22	39	16583	66679	90545146
Infusion related reaction	18.45	13.22	30	16592	416750	90195075
Retching	18.30	13.22	20	16602	19139	90592686
Vascular device infection	18.00	13.22	16	16606	11936	90599889
Dehydration	17.98	13.22	77	16545	194370	90417455
Lower respiratory tract infection	17.89	13.22	12	16610	250647	90361178
Plasma cell myeloma	17.77	13.22	29	16593	40799	90571026
Therapeutic reaction time decreased	17.69	13.22	10	16612	3648	90608177
Crohn's disease	17.56	13.22	11	16611	4840	90606985
Wheezing	17.53	13.22	11	16611	238069	90373756
Sarcoma	17.51	13.22	6	16616	658	90611167
Clostridium difficile colitis	17.48	13.22	23	16599	26683	90585142
Cholecystitis infective	17.45	13.22	8	16614	1884	90609941
Fibromyalgia	17.43	13.22	8	16614	206261	90405564
Colitis microscopic	16.93	13.22	15	16607	11144	90600681
Intestinal anastomosis complication	16.90	13.22	5	16617	341	90611484
Joint swelling	16.53	13.22	43	16579	503257	90108568
Urinary tract infection	16.40	13.22	104	16518	305528	90306297
Cholelithiasis	16.07	13.22	32	16590	52474	90559351
Alanine aminotransferase increased	16.05	13.22	53	16569	118285	90493540
Swelling	16.02	13.22	33	16589	419025	90192800
Hepatic steatosis	15.75	13.22	26	16596	36919	90574906
Aspartate aminotransferase increased	15.70	13.22	48	16574	102889	90508936
Weight decreased	15.54	13.22	121	16501	379789	90232036
Cholestatic liver injury	14.73	13.22	9	16613	3788	90608037
Remission not achieved	14.27	13.22	4	16618	225	90611600
Ileostomy	14.16	13.22	7	16615	1947	90609878
Tinnitus	14.08	13.22	27	16595	43075	90568750
Choking	14.08	13.22	14	16608	12019	90599806
Klebsiella infection	13.97	13.22	13	16609	10284	90601541
Thyrotoxic crisis	13.91	13.22	6	16616	1225	90610600
Discomfort	13.84	13.22	18	16604	274317	90337508
Blister	13.64	13.22	16	16606	254982	90356843
Diarrhoea haemorrhagic	13.58	13.22	13	16609	10650	90601175
Thyroidectomy	13.51	13.22	6	16616	1313	90610512
Benign vulval neoplasm	13.51	13.22	3	16619	64	90611761
Trance	13.51	13.22	3	16619	64	90611761
Gait inability	13.47	13.22	5	16617	146451	90465374
Neuropathy peripheral	13.25	13.22	55	16567	136915	90474910

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	91.86	16.09	262	8983	460587	42151503
Alveolar lung disease	80.77	16.09	19	9226	443	42611647
Pulmonary interstitial emphysema syndrome	77.04	16.09	19	9226	544	42611546
Diffuse alveolar damage	52.01	16.09	20	9225	2572	42609518
Intestinal intraepithelial lymphocytes increased	48.95	16.09	11	9234	208	42611882
Cryptitis	45.84	16.09	11	9234	280	42611810
Drug ineffective	43.39	16.09	258	8987	629939	41982151
Microvillous inclusion disease	42.51	16.09	10	9235	233	42611857
Nerve degeneration	38.84	16.09	9	9236	196	42611894
Intestinal obstruction	38.79	16.09	38	9207	27120	42584970
Apoptosis	38.07	16.09	11	9234	582	42611508
Product taste abnormal	37.70	16.09	13	9232	1226	42610864
Eosinophilic pneumonia	36.96	16.09	19	9226	4855	42607235
Probiotic therapy	35.41	16.09	8	9237	155	42611935
Faecal calprotectin increased	32.29	16.09	15	9230	3079	42609011
Abdominal rigidity	31.13	16.09	12	9233	1553	42610537
Hyperammonaemia	30.95	16.09	20	9225	7846	42604244
Hemivertebra	30.78	16.09	7	9238	140	42611950
Dehydration	29.32	16.09	82	9163	141685	42470405
Colitis microscopic	29.04	16.09	14	9231	3119	42608971
Vascular device infection	27.72	16.09	17	9228	6093	42605997
Gastric polyps	26.63	16.09	11	9234	1704	42610386
Small intestinal obstruction	26.48	16.09	25	9220	17036	42595054
Arthralgia	26.43	16.09	101	9144	205137	42406953
Erosive duodenitis	26.18	16.09	11	9234	1778	42610312
Transaminases abnormal	25.46	16.09	7	9238	309	42611781
Frequent bowel movements	25.20	16.09	27	9218	21380	42590710
Product solubility abnormal	25.03	16.09	8	9237	596	42611494
Biopsy	24.93	16.09	7	9238	334	42611756
Gastrointestinal anastomotic stenosis	24.77	16.09	5	9240	55	42612035
Abdominal pain	24.74	16.09	94	9151	190377	42421713
Hepatic enzyme abnormal	24.58	16.09	13	9232	3519	42608571
Fistula	23.71	16.09	17	9228	7895	42604195
Hepatic encephalopathy	23.46	16.09	23	9222	16419	42595671
Thyrotoxic crisis	22.50	16.09	8	9237	826	42611264
Enterocolonic fistula	22.08	16.09	5	9240	98	42611992
Escherichia urinary tract infection	22.02	16.09	13	9232	4350	42607740
Oesophageal atresia	21.89	16.09	7	9238	522	42611568
Renal mass	21.81	16.09	10	9235	1992	42610098
Glomerular filtration rate decreased	21.72	16.09	22	9223	16329	42595761
Renal neoplasm	21.36	16.09	9	9236	1466	42610624
Generalised oedema	21.04	16.09	21	9224	15315	42596775
Flatulence	20.08	16.09	26	9219	25126	42586964
Abdominal adhesions	19.92	16.09	9	9236	1733	42610357
Bacterial diarrhoea	19.28	16.09	5	9240	176	42611914
Intestinal stenosis	18.61	16.09	10	9235	2794	42609296
Toxicity to various agents	18.03	16.09	14	9231	229122	42382968
Bone density decreased	17.89	16.09	9	9236	2197	42609893
Lymphocyte count increased	17.65	16.09	11	9234	4053	42608037
Inappropriate schedule of product administration	17.43	16.09	53	9192	95849	42516241
Ileus	17.21	16.09	21	9224	19118	42592972
Rectal haemorrhage	17.08	16.09	35	9210	49571	42562519
Duodenitis	16.79	16.09	12	9233	5544	42606546
Hernia	16.75	16.09	16	9229	11057	42601033
Short-bowel syndrome	16.26	16.09	5	9240	328	42611762

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	160.25	13.24	513	19686	1138992	109430108
Pulmonary interstitial emphysema syndrome	79.88	13.24	19	20180	556	110568544
Alveolar lung disease	75.66	13.24	19	20180	700	110568400
Product solubility abnormal	66.62	13.24	19	20180	1143	110567957
Intestinal obstruction	66.40	13.24	64	20135	53163	110515937
Faecal calprotectin increased	63.96	13.24	29	20170	6690	110562410
Off label use	58.58	13.24	470	19729	1499715	109069385
Product physical consistency issue	58.34	13.24	18	20181	1422	110567678
Abdominal pain	53.51	13.24	210	19989	512779	110056321
Intestinal intraepithelial lymphocytes increased	49.69	13.24	11	20188	232	110568868
Diffuse alveolar damage	46.71	13.24	20	20179	4027	110565073
Vascular device infection	46.62	13.24	32	20167	16480	110552620
Small intestinal obstruction	46.47	13.24	42	20157	32171	110536929
Bowel movement irregularity	45.63	13.24	24	20175	7636	110561464
Cryptitis	44.43	13.24	11	20188	382	110568718
Drug ineffective	44.19	13.24	447	19752	1520093	109049007
Microvillous inclusion disease	42.85	13.24	10	20189	269	110568831
Drug ineffective for unapproved indication	40.94	13.24	70	20129	102768	110466332
Intestinal resection	40.72	13.24	18	20181	3911	110565189
Intestinal stenosis	40.65	13.24	19	20180	4696	110564404
Abdominal distension	40.51	13.24	95	20104	175008	110394092
Toxicity to various agents	38.31	13.24	20	20179	480535	110088565
Dehydration	38.12	13.24	125	20074	279386	110289714
Apoptosis	37.74	13.24	11	20188	715	110568385
Product taste abnormal	37.54	13.24	15	20184	2537	110566563
Nerve degeneration	37.40	13.24	9	20190	277	110568823
Thyrotoxic crisis	37.15	13.24	14	20185	2026	110567074
Probiotic therapy	36.03	13.24	8	20191	171	110568929
Frequent bowel movements	35.82	13.24	54	20145	71336	110497764
Eosinophilic pneumonia	35.69	13.24	20	20179	7207	110561893
Product residue present	34.35	13.24	16	20183	3925	110565175
Clostridium difficile infection	32.90	13.24	44	20155	52085	110517015
Therapeutic reaction time decreased	32.76	13.24	17	20182	5262	110563838
Anal fissure	32.35	13.24	21	20178	9860	110559240
Colitis	32.30	13.24	63	20136	102260	110466840
Product use complaint	31.79	13.24	15	20184	3788	110565312
Colitis microscopic	31.00	13.24	23	20176	13371	110555729
Abdominal adhesions	30.40	13.24	15	20184	4175	110564925
Cerebrovascular accident	30.23	13.24	87	20112	181197	110387903
Glossodynia	29.77	13.24	3	20196	222001	110347099
Flatulence	28.40	13.24	41	20158	52108	110516992
Blood pressure increased	27.87	13.24	107	20092	258266	110310834
Laparotomy	27.18	13.24	8	20191	538	110568562
Wound	27.12	13.24	5	20194	234432	110334668
Systemic lupus erythematosus	26.25	13.24	7	20192	254331	110314769
Rheumatoid arthritis	26.12	13.24	11	20188	299602	110269498
Inappropriate schedule of product administration	25.91	13.24	89	20110	203548	110365552
Psoriatic arthropathy	25.52	13.24	3	20196	196758	110372342
Erosive duodenitis	25.38	13.24	11	20188	2280	110566820
Enterocolonic fistula	25.21	13.24	6	20193	176	110568924
Hepatic encephalopathy	24.52	13.24	28	20171	28228	110540872
Gastrointestinal anastomotic stenosis	24.26	13.24	5	20194	74	110569026
Hyperammonaemia	24.04	13.24	20	20179	13712	110555388
Arthralgia	23.84	13.24	232	19967	779400	109789700
Gastric polyps	23.84	13.24	14	20185	5509	110563591
Cholangitis sclerosing	23.57	13.24	12	20187	3570	110565530
Contraindicated product administered	23.50	13.24	8	20191	248259	110320841
Mesenteric vein thrombosis	23.49	13.24	10	20189	1985	110567115
Gastrointestinal wall thickening	23.44	13.24	12	20187	3611	110565489
Abdominal rigidity	23.26	13.24	12	20187	3668	110565432
Intestinal anastomosis	22.90	13.24	8	20191	933	110568167
Functional gastrointestinal disorder	22.66	13.24	14	20185	6035	110563065
Poor venous access	22.48	13.24	25	20174	24497	110544603
Jaundice	21.85	13.24	39	20160	59197	110509903
Duodenitis	21.75	13.24	16	20183	9180	110559920
Terminal ileitis	21.70	13.24	9	20190	1675	110567425
Colectomy	21.31	13.24	12	20187	4366	110564734
Nephrolithiasis	21.17	13.24	41	20158	66171	110502929
Biopsy	20.75	13.24	7	20192	735	110568365
Drug level decreased	20.71	13.24	21	20178	18527	110550573
Folliculitis	20.67	13.24	3	20196	167650	110401450
Drug level above therapeutic	20.54	13.24	17	20182	11571	110557529
Lymphocyte count increased	20.43	13.24	14	20185	7189	110561911
Stomatitis	20.42	13.24	12	20187	270230	110298870
Blood alkaline phosphatase increased	20.37	13.24	42	20157	70893	110498207
Type 2 diabetes mellitus	20.03	13.24	4	20195	177228	110391872
Bile acid malabsorption	19.52	13.24	6	20193	468	110568632
Anal incontinence	19.46	13.24	22	20177	21942	110547158
Completed suicide	19.42	13.24	10	20189	242371	110326729
Fibromyalgia	19.02	13.24	4	20195	170905	110398195
Pleural rub	18.94	13.24	4	20195	67	110569033
Product odour abnormal	18.85	13.24	8	20191	1575	110567525
Transaminases abnormal	18.79	13.24	7	20192	981	110568119
Ileal stenosis	18.78	13.24	10	20189	3260	110565840
Arthropathy	18.76	13.24	15	20184	287507	110281593
Renal neoplasm	18.62	13.24	9	20190	2397	110566703
Proctalgia	18.60	13.24	17	20182	13205	110555895
Foreign body in throat	18.29	13.24	7	20192	1056	110568044
Serum ferritin increased	18.18	13.24	16	20183	11831	110557269
Ophthalmoplegia	18.01	13.24	10	20189	3540	110565560
Ileus	17.97	13.24	25	20174	30704	110538396
Hepatic steatosis	17.81	13.24	32	20167	48799	110520301
Renal mass	17.79	13.24	10	20189	3625	110565475
Ill-defined disorder	16.79	13.24	4	20195	156849	110412251
Drug interaction	16.78	13.24	42	20157	500141	110068959
Enteritis	16.65	13.24	19	20180	19137	110549963
Plasma cell myeloma	16.61	13.24	36	20163	62900	110506200
Bacterial diarrhoea	16.59	13.24	5	20194	365	110568735
Fistula	16.50	13.24	17	20182	15282	110553818
Intestinal anastomosis complication	16.17	13.24	5	20194	398	110568702
Weight decreased	16.14	13.24	143	20056	467914	110101186
Drug hypersensitivity	16.13	13.24	37	20162	454053	110115047
Glomerular filtration rate decreased	16.10	13.24	23	20176	28933	110540167
Impaired healing	15.93	13.24	8	20191	196709	110372391
Wheezing	15.80	13.24	14	20185	255216	110313884
Myopathy	15.64	13.24	21	20178	24939	110544161
Swelling	15.61	13.24	25	20174	351016	110218084
Myalgia	15.57	13.24	81	20118	222300	110346800
Generalised oedema	15.08	13.24	23	20176	30681	110538419
Heart rate decreased	15.04	13.24	41	20158	82715	110486385
Sarcoma	15.04	13.24	6	20193	1011	110568089
Rectal haemorrhage	14.91	13.24	52	20147	119781	110449319
Choking	14.88	13.24	16	20183	15094	110554006
Duodenal polyp	14.87	13.24	5	20194	520	110568580
Stoma complication	14.85	13.24	6	20193	1045	110568055
Hernia	14.73	13.24	18	20181	19482	110549618
Hepatic fibrosis	14.65	13.24	12	20187	8054	110561046
Infusion site extravasation	14.52	13.24	14	20185	11620	110557480
Therapeutic product effect decreased	14.42	13.24	14	20185	244302	110324798
Metastasis	14.39	13.24	12	20187	8255	110560845
Escherichia urinary tract infection	14.00	13.24	16	20183	16146	110552954
Gastroenteritis	13.61	13.24	25	20174	38775	110530325
Lung disorder	13.59	13.24	8	20191	180039	110389061
Vanishing bile duct syndrome	13.59	13.24	8	20191	3160	110565940
Benign vulval neoplasm	13.52	13.24	3	20196	64	110569036
Haematochezia	13.40	13.24	49	20150	115475	110453625

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AC01	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Bile acid sequestrants
FDA MoA	N0000175365	Bile-acid Binding Activity
FDA EPC	N0000180292	Bile Acid Sequestrant
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:35821	anticholesteremic drug
CHEBI has role	CHEBI:50671	antithyroid drug
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

C10AC Bile acid sequestrants 3 drugs

colesevelamcolestipolcolextran

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Hyperlipidemia	indication	55822004	DOID:1168
Biliary Obstruction with Pruritus	indication
Poisoning by digitalis glycoside	off-label use	12876009
Chronic diarrhea	off-label use	236071009
Classical phenylketonuria	contraindication	7573000
Constipation	contraindication	14760008	DOID:2089
Hypovolemia	contraindication	28560003
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hemorrhoids	contraindication	70153002	DOID:9746
Kidney disease	contraindication	90708001	DOID:557
Calculus in biliary tract	contraindication	266474003
Complete Biliary Obstruction	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018811	VUID
N0000147114	NUI
D02690	KEGG_DRUG
2447	RXNORM
CHEBI:749501	CHEBI
CHEMBL1201625	ChEMBL_ID
1005	INN_ID
DB01432	DRUGBANK_ID
4B33BGI082	UNII
4435	MMSL
6264	MMSL
d00193	MMSL
001216	NDDF
387408001	SNOMEDCT_US
72824008	SNOMEDCT_US
C0008402	UMLSCUI
4018811	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prevalite	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0036	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	24658-266	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	24658-270	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	24658-271	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	Human Prescription Drug Label	1	27241-134	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	20 sections
Cholestyramine	Human Prescription Drug Label	1	33342-293	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	Human Prescription Drug Label	1	33342-293	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	Human Prescription Drug Label	1	33342-319	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	42571-508	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	20 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-265	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-266	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	42806-267	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	42806-269	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	42806-270	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
CHOLESTYRAMINE LIGHT	HUMAN PRESCRIPTION DRUG LABEL	1	42806-271	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	49884-465	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	49884-466	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
QUESTRAN	HUMAN PRESCRIPTION DRUG LABEL	1	49884-936	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
QUESTRAN	HUMAN PRESCRIPTION DRUG LABEL	1	49884-937	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	22 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3415	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
CHOLESTYRAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3845	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	12 sections
Cholestyramine Light	HUMAN PRESCRIPTION DRUG LABEL	1	51224-009	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	23 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	51224-011	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4812	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	14 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5526	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	14 sections
Cholestyramine for Oral Suspension	HUMAN PRESCRIPTION DRUG LABEL	1	62135-008	POWDER	4 g	ORAL	ANDA	13 sections
Cholestyramine for Oral Suspension	HUMAN PRESCRIPTION DRUG LABEL	1	62135-937	POWDER	4 g	ORAL	ANDA	13 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2162	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
Cholestyramine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2164	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	21 sections
cholestyramine powder for suspension	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9196	POWDER, FOR SUSPENSION	4 g	ORAL	ANDA	19 sections